Clinical Trial Update: Azithromycin and Coronary Events Study (ACES) [Phase 3]

View source ↗

Summary

Phase 3 trial ACES evaluating azithromycin for preventing coronary events has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Diseases
• Coronary Artery Disease
• Myocardial Infarction

Drugs mentioned

• Azithromycin (azithromycin)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Coronary Disease, Heart Diseases | Phase 3 | Status: COMPLETED